Posted by Michael Wonder on 24 Dec 2022
Neurocrine Biosciences announces US FDA accepts supplemental new drug application for valbenazine as a treatment for chorea associated with Huntington disease
22 December 2022 - PDUFA target action date set for 20 August 2023.
Neurocrine Biosciences today announced that the US FDA has accepted its supplemental new drug application for valbenazine as a treatment for chorea associated with Huntington disease.
